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Abstract
Objectives: The aim of the present superiority study was to determine the effect of 
systemic antibiotics primarily on patient-reported outcome measures (PROMs) and 
post-surgical complications in patients undergoing oral implant therapy with simulta-
neous guided bone regeneration (GBR).
Materials and Methods: A total of 236 medically and periodontally healthy patients 
received oral implants with simultaneous GBR at seven centres. Pre-operative anti-
biotics of 2 g amoxicillin were prescribed to the test group 1 hr prior to surgery and 
500 mg thrice daily on days 1–3 after surgery. The control group was given a placebo. 
Group allocation was performed randomly. Primary outcome variables were PROMs 
recorded as visual analogue scale scores assessed on days 1–7 and 14 on pain, swell-
ing, haematoma and bleeding. Post-operative complications as secondary outcome 
variables were examined at 1, 2, 4 and 12 weeks from surgery. Chi-square tests and 
repeated measures of analysis of variance (ANOVA) were performed for statistical 
evaluation.
Results: No statistically significant differences (p > .05) between the two groups 
were detected for the evaluated PROMs. The same was noted with respect to post-
surgical complications. Four implants were lost—three in the test group and one in 
the control group.
Conclusion: In this trial, systemic antibiotics did not provide additional benefits to 
PROMs, nor the prevention of post-surgical complications in medically and perio-
dontally healthy patients undergoing oral implant therapy with simultaneous GBR. 
However, further studies with larger sample sizes are still required to support the 
clinical outcomes of this study.
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1  | INTRODUC TION
The use of systemic oral antibiotics as prophylaxis against 
post-surgical infection in implant dentistry has been documented 
(Esposito, Grusovin, & Worthington, 2013). However, recommen-
dations with regard to antibiotic prophylaxis in guided bone re-
generation procedures are often based on personal and anecdotal 
experience (Deeb, Soung, Best, & Laskin, 2015; Suda, Henschel, 
Patel, Fitzpatrick, & Evans, 2017). With the increasing worldwide 
demand for oral implants and oral bone augmentation procedures 
and the development of antibiotic resistance due to indiscriminate 
usage, the use of antibiotics with standard oral implant therapy 
and GBR should be re-evaluated and proper guidelines established 
(Tan et al., 2014).
Furthermore, there is emerging evidence of significant long-
term implications of systemic antibiotics due to disturbance 
of the body's microbial balance, in particular with regard to the 
gastrointestinal microbiota. New evidence has indicated the use 
of systemic antibiotics to be connected with nutrition disorders, 
obesity, chronic psycho-social stress-induced conditions and im-
mune system deregulation due to major disturbance of the bacte-
rial equilibrium of the gastrointestinal system (Rosa, Brancaglion, 
Miyauchi-Tavares, Corsetti, & Almeida, 2018; Vemuri et al., 2018). 
In light of such findings, the question of whether the potential 
benefit of antibiotic prophylaxis with oral implant therapy and 
GBR outweighs the long-term risks or even the short-term med-
ication-related side effects such as diarrhoea, rashes or fungal 
infections remains to be determined. There is a long history of 
antibiotics being used as surgical prophylaxis to accompany the 
placement of dental implants, a practice that evolved due to a lack 
of awareness regarding the potential harmful effects of antibiot-
ics and the growing bacterial resistance. It is therefore necessary 
to scrutinize the concept of routine administration of antibiotics 
in systemically healthy patients undergoing oral implant therapy 
(Park, Tennant, Walsh, & Kruger, 2018).
In the field of oral implant therapy and GBR, the use of sys-
temic antibiotics remains a controversial issue, with various antibi-
otic regimes being advocated (Powell, Mealey, Deas, McDonnell, & 
Moritz, 2005). Some authors did not find additional benefits with 
the use of antibiotics when compared to controls. In two random-
ized controlled clinical trials (Abu-Ta'a, 2008; Tan et al., 2014), the 
authors found no significant advantages pertaining to post-sur-
gical infection and complications with the use of peri-operative 
antibiotics for standard oral implant therapy. Also, Park et al. con-
cluded, in a recent systematic review, that antibiotic use in healthy 
patients for the prophylaxis of surgical infection associated with 
oral implant therapy does not appear to improve clinical outcomes. 
They further suggested that practitioners should apply principles 
of antimicrobial stewardship and not use antibiotics as a routine 
measure in healthy patients (Park et al., 2018). Despite ongoing 
multinational attempts to enforce awareness of antimicrobial re-
sistance, the abuse of antimicrobials may in part be elicited by 
patient demand in a bid to avoid infections. Often, there may be 
a misunderstanding by patients in what signs or symptoms consti-
tute an infection, and as such, clinicians may feel pressurized into 
prescribing antibiotics unnecessarily. As such, studies considering 
patient outcomes may be of benefit in providing evidence towards 
appropriate antimicrobial stewardship.
Due to a lack of randomized controlled clinical trials investigating 
the effect of systemic antibiotics on post-surgical complications with 
oral implant therapy and simultaneous GBR so far, there is no clear 
evidence to recommend the use of routine antibiotics to prevent in-
fections for this indication as well.
As such, studies implicated in supporting the avoidance of exces-
sive antibiotic usage would likely need to show no additional bene-
fits to the effects of treatment with antibiotics as a means of proving 
consistency and avoidance of detrimental outcomes.
This multicentre randomized clinical trial (RCT) was designed as 
superiority study aiming to investigate the effect of systemic antibi-
otics primarily on patient-reported outcome measures (PROMs) and 
secondarily on post-surgical complications in medically and peri-
odontally healthy patients undergoing oral implant therapy and si-
multaneous GBR. The null hypothesis tested was that there were no 
differences in PROMs following treatment and post-surgical compli-
cations between the two groups tested.
2  | MATERIAL AND METHODS
This study was initiated as a subsequent study to the paper pub-
lished by Tan et al. (2014), which explored the effects of antibiotic 
intervention on conventional oral implant therapy. As a development 
of that investigation, this study aimed to consider how the addition 
of GBR may affect these post-surgical outcomes—where in the origi-
nal paper simple implant placement heralded no impact whatsoever 
on both PROMs nor post-surgical complications.
2.1 | Subject population
The following seven study centres belong to the Antibiotic Research 
Group and were included as part of the multicentre trial:
1. Department of Oral Surgery and Orthodontics, Graz Austria, 
Medical University Graz, University Clinic of Dental Medicine 
& Oral Health;
K E Y W O R D S
biomaterials, bone regeneration, bone substitutes, drug delivery, guided tissue regeneration, 
patient-centred outcomes, pharmacology
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2. National Dental Centre Singapore, Singapore;
3. Peking University, School of Stomatology, Beijing PR China;
4. Griffith University, Gold Coast, School of Dentistry and Oral 
Health, Queensland, Australia;
5. The University of Hong Kong, Faculty of Dentistry, Hong Kong 
SAR PR China;
6. University of Iceland, Faculty of Odontology, Reykjavik, Iceland; 
and
7. Shanghai Jiao Tong University, Shanghai Ninth People's Hospital, 
Department of Implant Dentistry, Shanghai PR China
Subjects were recruited across all centres, between August 2014 
and September 2017.
The study protocol was submitted to and approved by the re-
spective institutional review boards of the seven institutions. 
Subjects were screened consecutively and selected through regular 
implant assessment clinics by calibrated examiners at each centre. 
Patients that were enrolled fulfilled the following inclusion criteria:
• Medically healthy with no known allergy to amoxicillin or penicil-
lin antibiotics and/or starch.
• No administration of any form of antibiotics in the last 6 months.
• Non-smoker or light smoker or a previous smoker who had quit 
for 5 years or more.
• Periodontal health, as confirmed by clinical examination (Heitz-
Mayfield, Needleman, Salvi, & Pjetursson, 2014; Matuliene et al., 
2008).
• Edentulous space (up to 3 units), with a horizontal bone defect 
suitable for implant placement with simultaneous GBR—in cases 
requiring multiple implant placement, one study implant was 
selected randomly after surgery and included for further study 
assessments.
Medical health was assessed with the help of standardized 
health questionnaires. Study enrolment was limited to subjects 
aged ≥ 21 years with a score of 1 or 2 according to the physical sta-
tus classification of the American Society of Anesthesiologists (ASA) 
(Mak, Campbell, & Irwin, 2002).
Medically compromised subjects (ASA classification III-V), gen-
eral contraindications against implant treatment or augmentative 
procedures (e.g. immunodeficiency, advanced systemic diseases, 
corticosteroid medication), and treatments or diseases that may 
have an effect on bone turnover or bone or non-mineralized tissue 
metabolism (e.g. bisphosphonates or local radiotherapy) were rea-
sons for exclusion from the study.
Periodontal and radiographic examinations were performed in-
cluding assessment of probing depth (PD) and Bleeding on Probing 
(BOP). Further, full-mouth bleeding scores and full-mouth plaque 
scores were obtained.
Only patients with PD < 5 mm without concomitant bleeding, 
full-mouth bleeding score and full-mouth plaque score of <20% 
were included in order to reduce the risk of subsequent biological 
complications such as peri-implantary and periodontal infections 
as described by Matuliene and co-workers and Heitz-Mayfield and 
co-workers (Heitz-Mayfield et al., 2014; Matuliene et al., 2008).
Furthermore, the dimensions of the edentulous sites were an-
alyzed with the help of two and if necessary three-dimensional ra-
diographs in order to ensure suitability for a simultaneous surgical 
protocol prior to the intervention.
The included cases were considered as “advanced” according 
to the Straightforward/Advanced/Complex (SAC) classification in 
implant dentistry (Dawson et al., 2009) allowing implant placement 
and simultaneous GBR as described by Hämmerle and co-workers 
(Hämmerle, Chiantella, Karring, & Lang, 1998).
All patients were fully informed regarding the purpose of the 
study and the risks and benefits associated with participation. 
Signed informed consent was obtained by all patients.
2.2 | Investigator training
The study was designed as RCT, with two arms (one test group and 
one control). The examiners and patients were blinded. Prior to the 
commencement of the study, a whole day investigator and examiner 
training was held during the ITI World Congress in 2014 in Geneva: 
Each centre sent one representative centre coordinator to partici-
pate in the training and who would manage the further internal train-
ing (surgeons, examiners and patients) at the different centres. Up 
to four surgeons were allowed to perform the clinical procedures in 
each centre, but only one could be enrolled as the clinical examiner.
For both clinical examiners and surgeons, all relevant steps 
were outlined by M.P., N.P.L. and N.M. in oral and with the help of a 
Microsoft® PowerPoint® presentation (ppt®) (Microsoft, Redmond, 
USA). The instructions during the training were given in chronologi-
cal order based on the study protocol; this included pre-treatments, 
patient selection, periodontal examination, intraoperative steps, 
study medication, post-operative assessments and complication 
management. At the end of the meeting, the ppt® presentation 
was handed over to the participants of the meeting to be used for 
further training at their centre. The further centre screenings were 
performed in a consecutive manner in meetings in 2016, 2017 and 
2018. Again, one representative of each centre was present at the 
meetings to report on the current status of the investigation at each 
centre. Although all investigators were trained in the study proceed-
ings, they may not be considered properly calibrated.
2.3 | Clinical procedures
A list of randomized allocation with block size of 4 was generated 
for each of the centres by a statistician not involved in the clinical 
procedures and data collection. Patients recruited were randomized 
to the test and control groups following the randomized allocation.
The study medication was prescribed by a designated clinical 
coordinator from the centre, who was not involved as a surgeon or 
examiner. The surgeons involved had no access to the data collection 
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sheets or the group allocation, whilst the examiner had no access 
to the patients' treatment notes or group allocation. Randomization 
was performed at the time of consent owing to the fact that the test 
and the control groups had to take the medication prior to implant 
placement.
2.4 | Study medication
The placebo and test products were prepared, identically packed and 
numbered in a certified laboratory (Allerheiligen Apotheke Herbert 
Baldia KG, Vienna, Austria) and distributed to the study centres. The 
centres were not aware of the medication codes.
Two hours prior to surgery, each subject received a box with a 
numbered code (according to group allocation but not readable for 
the patient; all containers were unmarked but identical) containing 
medication or placebo with a detailed written instruction on tim-
ing and dosage of consumption of the medication/placebo on top. 
Additionally, a verbal instruction was performed by the person per-
forming surgery (different to the blinded examiner responsible for 
the assessment of clinical parameters).
• In the test group, pre-operative administration of 2 g amoxicillin 
(Moxilen® Medochemie, Cyprus) 1 hr prior to implant placement 
and GBR was administered. An additional single dose of 500 mg 
of amoxicillin was given 8 hr after surgery and 500 mg thrice 
daily (8 hourly) on days 1–3 following implant placement and 
GBR.
• In the control group, a pre-operative placebo (containing corn 
starch) of 2 g was administered. An additional single dose of 
500 mg of placebo was administered 8 hr after surgery and 
500 mg thrice daily (8 hourly) on days 1–3 following implant place-
ment and GBR.
2.5 | Surgical protocol
Each patient rinsed for 1 min with 0.2% chlorhexidine prior to sur-
gery. Aseptic isolation of the operative field was ensured. After local 
anaesthesia, a crestal incision was performed and complimentary 
mesial or distal releasing incisions were utilized if needed in order to 
reflect a full-thickness flap and expose the full margins of the bone 
defect.
The bony dimensions (bucco-lingual width of alveolar bone/
buccal bony plate thickness and mesio-distal width of alveolar bone) 
of the surgical site were clinically recorded during surgery with the 
help of a calliper and the soft tissue flap thickness record with a 
University of North Carolina 15 probing instrument.
Osteotomies were carried out to the length and diameter of the 
implants indicated—Straumann Standard Plus® or Straumann Bone 
level®—Sand-blasted Long grit Acid-etched implants of diameters 
3.3, 4.1 and 4.8 mm and 8–12 mm in the length (Straumann AG).
The simultaneous bone augmentation procedures were car-
ried out using bovine hydroxyapatite (Bio-Oss®, 0.5 g/0.25–1 mm 
particle size, Geistlich, Wolhusen, Switzerland) and resorbable col-
lagen membranes (Bio-Gide®; Geistlich). Special care was taken 
to achieve tension-free wound closure for either submerged or 
transmucosal healing using monofilament sutures, and horizontal 
periosteal release incision in the apical margin of the flap was uti-
lized if needed, by means of a partial-thickness dissection. After 
surgery, intraoral baseline radiograph and post-operative occlusal 
photographs were taken. All groups were advised to take analge-
sics (paracetamol) thrice daily for two days after surgery and asked 
to document their intake. Patients were further instructed to use a 
0.2% chlorhexidine mouth rinse twice daily for 2 weeks. One week 
after surgery, sutures were removed and post-operative occlusal 
photographs were taken.
2.6 | Clinical measurements
Dichotomous measurements Yes/No (Y/N) for pain, swelling, im-
plant stability, purulent discharge and flap closure were collected by 
one blinded examiner in each centre at 1, 2, 4 and 12 weeks after 
the surgery. The clinical examiner was not involved in the surgical 
procedure and blinded to the antibiotic group allocation.
2.7 | Patient-reported outcome measures
All patients filled a set of visual analogue scale (VAS) forms for the 
assessment of four healing parameters pain, swelling, haematoma 
and bleeding over the first two post-operative weeks. Each param-
eter was expressed by a 10 cm VAS extending from 0 (e.g. no swell-
ing) to 10 (e.g. very severe swelling). Patients were requested to 
express the level of each parameter as they experience it every day 
by indicating a mark along the VAS. Compliance in completing the 
records of VAS and analgesic consumption forms was monitored at 
the follow-up visits.
For the submerged implants, second-stage surgery was per-
formed 12 weeks after implant placement and a healing abutment 
inserted.
Impressions were taken 12 (for the non-submerged) and 14 
weeks (for the submerged) after implant placement, and 7–14 days 
later, single-tooth crowns were inserted onto the implants.
2.8 | Statistical analysis
Primary outcome variables of the study were PROMs as recorded in 
the VAS scores (0–10) assessed on days 1–7 and 14 on pain, swelling, 
haematoma and bleeding.
Secondary outcome variables were the presence of post-surgical 
complication pain, swelling, implant stability, purulent discharge and 
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flap closure assessed by clinical examination in a dichotomous man-
ner at 1, 2, 4 and 12 weeks.
Chi-square (or chi-square exact) tests were used to compare the 
percentage distribution of post-surgical complications at weeks 1, 2, 
4 and 12 between the test and control groups. Student's t tests and 
Mann–Whitney U tests were used to compare the mean and median 
VAS scores of the PROMs, respectively, at day 14 between the test 
and control groups. Repeated-measures ANOVA was performed on 
the VAS scores of the PROMs with the use of multivariate tests (Wilks' 
lambda) for the effect of time and the interaction effect between treat-
ment groups and time (all effects considered to be fixed). The above 
analyses were performed using SPSS®. To adjust the possible centre 
effect, a random effect for centre (different centres considered to be a 
random sample of centres) was added to the above repeated-measures 
ANOVA using SAS®. The centre effect was evaluated when perform-
ing repeated-measures ANOVA for PROMs.
2.9 | Sample size
Sample size estimation was calculated based on a superiority trial, 
using software G*Power® version 3.1.9.2. The standard deviations 
of the PROMs based on the Tan et al. (2014) study were mostly 
ranged from 1.0 to 2.0. An effect size of 0.40 (moderate effect) in 
the differences in the mean VAS scores of the PROMs between the 
test and control group was considered to be of clinical importance. 
This corresponded to a minimum important difference of 0.4 to 0.8 
in mean VAS scores. With this consideration, the required sample 
size would be 100 for each group when the level of significance was 
set at 0.05 (2-sided test) and power to be 80%. Accounting for a 
dropout rate of 10%, a minimum of 110 patients per group were 
planned for recruitment.
3  | RESULTS
Altogether, 253 data entries in the raw data file were received 
from the seven study centres: 17 primarily included cases had to be 
excluded due to heterogenous reasons such as unknown allergies/
sensitivities towards the study medications (placebo or amoxicil-
lin), lack of compliance with study appointments or incomplete/
unreproducible data completion. Thus, a total of 236 cases were 
analysed—117 patients in the test group and 119 patients in the 
control group (Table 1). No significant differences (all p > .05) in 
patient profile among the two treatment groups in terms of age, 
gender and implant dimensions could be observed (Table 2).
The surgical procedures of all 236 subjects were uneventful. 
Four implants were lost—three in the test group and one in the con-
trol group. This reveals an overall implant survival rate of 98.3% for 
all study implants, 97.4% for implants in the test group and 99.2% for 
implants in the control group. There were no statistically significant 
differences in implant survival rate between the test and control 
groups (p > .05).
3.1 | Use of analgesics
The percentage of patients who took analgesics did not differ sig-
nificantly (p > .05) between the two treatment groups over the post-
operative observation period (Table 3).
3.2 | Patient-reported outcome measures
There were no statistically significant differences in the mean and 
median VAS scores of bleeding, swelling, pain and haematoma be-
tween the two treatment groups at day 14 (all p > .05). Results 
from the repeated-measures ANOVA confirmed that there were 
no statistically significant differences between the two treatment 
groups for bleeding, swelling, pain and haematoma (all p > .05; 
Figures 1‒4). However, there was a significant time effect, where 
the mean VAS scores decreased over time (p < .001). No signifi-
cant interaction effect between the treatment groups and time 
suggested that the decrease in the mean VAS scores in different 
treatment groups was not significantly different from each other 
for all the variables assessed.
When adjusted for the centre effect, there was a significant cen-
tre effect (p < .001); that is, different centres were having different 
mean VAS scores mainly in the first few days. For example, Centre 
4 had higher mean VAS scores in bleeding than Centre 5 from day 1 
to day 3, but since day 4, no significant difference could be detected 
any more.
3.3 | Post-surgical outcomes
Thirteen cases had incomplete post-surgical outcome. However, 
data from 113 patients in the test group and 110 patients in the 
control group were analysed. There were no statistically significant 
differences in flap closure, pain, swelling, pus and implant stability 
of the operation site between the two treatment groups at any time 
(p > .05; Table 4).
TA B L E  1   Recruitment of patients at seven study centres 
(T = test group/C = control group)
 
Group
C T Total 
Centre
1 12 12 24
2 27 24 51
3 20 21 41
4 11 9 20
5 10 10 20
6 26 27 53
7 13 14 27
Total 119 117 236
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4  | DISCUSSION
The present study was aiming to determine the effect of systemic 
antibiotics on PROMs and post-surgical complications in patients 
undergoing oral implant therapy with simultaneous GBR. In this 
instance, PROMs of 236 cases—117 patients in the test group 
and 119 patients in the control group—were assessed as primary 
outcome measures relating to pain, swelling, bleeding and haema-
toma. Results from the repeated-measures ANOVA revealed no 
statistically significant differences between the two treatment 
groups.
As secondary outcome variable of this study, the evaluation of data 
from 113 patients in the test group and 110 patients in the control 
group for the assessment of post-surgical complications showed no 
statistically significant differences in flap closure, pain, swelling, pus 
and implant stability of the operation site between the two groups.
It could be argued that the absence of significant differences in 
the secondary outcome variables in this trial might be due to the low 
prevalence of post-surgical complications, and therefore, the study 
might not have enough power to find the existence of difference 
for these outcomes. However, although there were no statistically 
significant differences in post-surgical complications, clinically dif-
ferences, for example in regard to suppuration, which was greater in 
the control group, could influence clinical behaviours with regard to 
the prescription of systemic antibiotics.
Beyond the administration of antimicrobials, analgesic con-
sumption was documented in the present trial and was higher in 
the control group from day zero until day 14 after surgery. Again, 
the difference was not statistically significant; however, clinical in-
terpretation of this outcome may be different in general practice 
setting.
 C (n = 119) T (n = 117) Total (n = 236) p-Value
Age (Mean) 44.8 47.2 46.0 .196
Gender (%)
Male 55.5 50.4 53.0 .438
Female 44.5 49.6 47.0
Diameter of the implants used (%)
3.3 mm 32.8 32.5 32.6 .699
4.1 mm 47.0 51.3 49.2
4.8 mm 20.2 16.2 18.2
Length of the implants used (%)
8 mm 11.8 5.1 8.5 .159a
10 mm 58.0 70.1 64.0
12 mm 26.9 22.2 24.6
14 mm 3.3 2.6 2.9
aChi-square exact test. 
TA B L E  2   Baseline characteristics 
of the subjects and clinical parameters 
in different groups (T = test 
group/C = control group)
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 14
C (n = 119) 47.9 46.2 36.8 26.7 18.8 16.2 9.3 4.2
T (n = 117) 46.2 36.8 30.8 20.7 16.4 11.4 6.3 2.6
Total 47.0 41.5 33.8 23.7 17.6 13.9 7.8 3.4
p-Value .793 .144 .333 .280 .627 .287 .386 .722a
aChi-square exact test. 
TA B L E  3   Percentages of subjects 
who took analgesics (n = 236) (T = test 
group/C = control group)
F I G U R E  1   Mean ± SD (standard deviation) visual analogue scale 
(VAS) of bleeding (Bleeding-VAS) from day 1 to day 14. (T = test 
group/C = control group)
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In the present trial, a total of four out of 236 implants were 
lost—three in the test group receiving oral antibiosis and one in the 
control group without antibiotic prophylaxis. This corresponds to an 
overall implant survival rate of 98.3% for all study implants, 97.4% 
for implants in the test group and 99.2% for implants in the control 
group. Survival rates are in accordance with those of other studies 
and show no statistically significant difference between the two 
treatment groups (Jemt, 2018).
Since implant survival (incorporation rate) is very high in todayʼs 
clinical practice, most of the studies addressing this parameter in re-
lation to peri-operative antibiotic prophylaxis must be considered as 
underpowered (Esposito, Grusovin, Loli, Coulthard, & Worthington, 
2010). Only the meta-analysis of four underpowered studies 
(Abu-Ta'a et al., 2008; Anitua et al., 2009; Esposito, Cannizzaro, 
et al., 2010; Esposito et al., 2008) revealed a risk ratio of 0.4 (95% 
Confidence Interval: 0.19–0.84) for early implant failures. As indi-
cated above, these implant failures cannot be taken as evidence of 
the beneficial effect of peri-surgical prophylactic antibiotics, owing 
to the presumptive surgical confounders. In the meta-analysis of the 
four studies mentioned, the risk ratio for post-surgical infection was 
0.74 (95% CI: 0.37–1.47). In this relevant parameter for the effect of 
peri-operative antibiotic administration, statistical significance was 
not reached indicating a lack of benefit from the antibiotic regimes.
In the following systematic Cochrane review including six RCTs 
(1,162 patients) by Esposito et al., the authors concluded antibiotics 
to be beneficial for reducing failure of dental implants placed in or-
dinary conditions. Specifically, a single oral administration of two or 
three g one hour pre-operatively seemed to reduce failure of dental 
implants (Esposito et al., 2013).
However, it is crucial to be aware that this Cochrane review 
considered implant failures as a specific point of assessment rather 
than PROMs. It is also worth considering the studies included in 
this review maintained similar clinical standards to this paper 
(such as systemic and periodontal health), and several followed 
similar peri-operative protocols, for example the use of chlorhex-
idine rinse (Anitua et al., 2009; Caiazzo, Casavecchia, Barone, & 
Brugnami, 2011; Esposito, Cannizzaro, et al., 2010; Esposito et al., 
2008; Esposito, Grusovin, et al., 2010). Nonetheless, there were 
notable variations in protocols, such as in the paper by Nolan and 
F I G U R E  2   Mean ± SD (standard deviation) visual analogue scale 
(VAS) of swelling (Swelling-VAS) from day 1 to day 14. (T = test 
group/C = control group)
F I G U R E  3   Mean ± SD (standard deviation) visual analogue 
scale (VAS) of pain (Pain-VAS) from day 1 to day 14 (T = test 
group/C = control group)
F I G U R E  4   Mean ± SD (standard deviation) visual analogue 
scale (VAS) of haematoma (Haematoma-VAS) from day 1 to day 14 
(T = test group/C = control group)
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co-workers where no post-operative medication was prescribed to 
either group and in Anitua et al. where a preparation rich in growth 
factor (PRGF) was included in the operative protocol and post-op-
erative steroids, which could have impacted post-operative heal-
ing patterns (Anitua et al., 2009; Nolan, Kemmoona, Polyzois, & 
Claffey, 2014).
Furthermore, work by Esposito and co-workers explored anti-
biotics in treatment outcomes but only compared test and placebo 
groups in the pre-operative setting and included a large variety of 
implant procedures; results noted no statistically significant differ-
ences between either group (Esposito, Cannizzaro, et al., 2010).
It should be noted that both in the preceding trial by Tan et al. 
and in this study, the administration of pre-, peri- or post-surgical 
prophylactic antibiotics did not influence the wound healing pattern, 
the subjective variables nor general implant survival at all (Tan et al., 
2014). This may be as a result of the high standards of infection con-
trol expected of the implant surgical procedures at all the centres 
participating in this study. Further, all included patients had been 
treated periodontally prior to implant installation.
In spite of differences in PROMs between the centres, consis-
tent overall results were obtained. However, in this context it should 
be mentioned that the sample size calculation expected to detect 
differences in the outcomes only with 100 subjects required per 
arm. As no centre reached that figure, no statistically significant dif-
ferences could be expected.
In the present study, no technical complications were diagnosed 
within the observation period irrespective of the group allocation of 
the patients. This may be due to the fact that only one implant sys-
tem was used, thus minimizing the various possibilities of technical 
complications.
On the other hand, biological complications (peri-implant muco-
sitis, peri-implantitis) have to be considered as generic and not re-
lated to implant systems (Abrahamsson, Berglundh, & Lindhe, 1998; 
Albouy, Abrahamsson, Persson, & Berglundh, 2008, 2009). In addi-
tion, to minimize further confounding factors only one bone substi-
tute and type of barrier membrane were used in this trial.
When interpreting the results of this trial, it has to be considered 
that only subjects with defects allowing simultaneous implant inser-
tion and GBR were admitted. Therefore, no statement on the ne-
cessity of antibiotic prophylaxis during treatment of highly atrophic 
sites in a staged approach can be made. The included cases were 
considered as “advanced” according to the SAC classification in im-
plant dentistry (Dawson et al., 2009) allowing a simultaneous fixture 
placement and grafting approach.
 C (n = 110) T (n = 113) Total (n = 223) p-value
Flap closure
1 week 83.6 87.6 85.7 .397
2 weeks 82.7 77.9 80.3 .363
4 weeks 90.0 84.1 87.0 .188
12 weeks 83.6 84.1 83.9 .930
Pain
1 week 30.0 26.5 28.3 .567
2 weeks 10.9 10.6 10.8 .944
4 weeks 8.2 3.5 5.8 .139
12 weeks 2.7 0.9 1.8 .365a
Swelling
1 week 42.7 38.9 40.8 .565
2 weeks 13.6 18.6 16.1 .315
4 weeks 2.7 2.7 2.7 1.000a
12 weeks 0.9 1.8 1.3 1.000a
Pus
1 week 3.6 1.8 2.7 .442a
2 weeks 1.8 0.9 1.3 .618a
4 weeks 0.9 0.9 0.9 1.000a
12 weeks 1.8 0.0 0.9 .242a
Implant stability
1 week 99.1 100.0 99.6 .493a
2 weeks 99.1 100.0 99.6 .493a
4 weeks 98.2 97.3 97.8 1.000a
12 weeks 99.1 97.3 98.2 .622a
aChi-square exact test. 
TA B L E  4   Percentages of subjects with 
post-surgical outcome variables in the 
different groups at weeks 1, 2, 4 and 12 
after surgery (T = test group/C = control 
group)
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The broad-spectrum antibiotic used was amoxicillin (Moxilen® 
Medochemie, Cyprus), a well-documented semi-synthetic analogue 
of ampicillin, derived from the basic penicillin nucleus (6-aminope-
nicillanic acid) providing a broad spectrum of bactericidal activity 
against many gram-positive and gram-negative microorganisms 
(Suda et al., 2017). It is, however, susceptible to degradation by β-lac-
tamases, and therefore, its spectrum of activity does not include 
organisms producing these enzymes. Nevertheless, amoxicillin was 
chosen as the antibiotic of choice in this study as it is considered a 
suitable first-line agent, demonstrating a high level of antimicrobial 
activity in patients with dento-alveolar infections (Kuriyama et al., 
2007).
The pre-operative dosage of amoxicillin applied in the preceding 
study published by Tan et al. was based on the antibiotic dosage rec-
ommendation by the American Heart Association (AHA) for preven-
tion of infective endocarditis (Wilson et al., 2007).
In subjects with increased systemically risk factors, such as an-
tiresorptive therapy, successful implant therapy is feasible—however, 
an individual risk assessment taking the primary disease and medi-
cation(s) into account with regard to further compromise to wound 
healing seems mandatory. Walter and co-workers further concluded 
that in these types of compromised patients, bone augmentations 
should be avoided, and peri-operative antimicrobial prophylaxis is 
highly recommended (Walter, Al-Nawas, Wolff, Schiegnitz, & Grötz, 
2016).
In conclusion, it appears that systemic antibiotics do not provide 
any improvement in PROMs in healthy patients undergoing oral im-
plant therapy and simultaneous GBR in comparison with a placebo 
group. Furthermore, between the two groups tested, there was also 
no significant reduction in post-surgical complications. However, it is 
crucial to remember that underpowering must be considered when 
interpreting the clinical outcomes of this trial.
To what extent antibiotics may be indicated to improve PROMs 
for complex staged or other wide-ranging implant procedures, such 
as sinus augmentation procedures, remains to be explored in future 
trials of the study group.
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